New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
11:12 EDTSGMO, NVS, XPO, TSRA, NWLHigh option volume stocks: SGMO NVS XPO TSRA NWL
News For SGMO;NVS;XPO;TSRA;NWL From The Last 14 Days
Check below for free stories on SGMO;NVS;XPO;TSRA;NWL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2014
12:06 EDTNVSNovartis treatment for pigmented villonodular synovitis gets orphan designation
According to a post on the FDA's website, Novartis' recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor received orphan designation. Reference Link
05:17 EDTNVSNovartis provides drug candidate compounds to TB Alliance
Subscribe for More Information
August 19, 2014
05:11 EDTNVSGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information
August 18, 2014
07:35 EDTNVSApricus Biosciences launches topical ED treatment in Germany
Subscribe for More Information
August 17, 2014
20:39 EDTTSRAPatent overhaul efforts seem to have stalled before November election, WSJ says
Legal experts say that it is unlikely that a full Congress will revisit the issue of patent reform before the election in November, says the Wall Street Journal. Large technology companies like Google (GOOG) and Microsoft (MSFT) are pushing Congress to reform patent laws to curb litigation from patent-holding firms, added the Wall Street Journal. Publicly traded companies in the space include Acacia Research (ACTG), Tessera (TSRA), Rambus (RMBS) InterDigital (IDCC) and Vringo (VRNG). Reference Link
August 15, 2014
08:56 EDTNWLSpectrum Brands announced Douglas Martin to join company as CFO
Martin will join the company as its new Executive VP and CFO effective on September 1. Martin had served as Executive VP and CFO of Newell Rubbermaid.
August 14, 2014
16:14 EDTNWLNewell Rubbermaid announces resignation of CFO Doug Martin
Subscribe for More Information
August 11, 2014
15:27 EDTSGMOWedbush to hold a conference
Life Sciences Management Conference to be held in New York on August 12-13.
05:18 EDTNVSNovartis reports LCZ696 significantly reduced cardiovascular deaths
New data revealing the reduction in cardiovascular, or CV, deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction, or HF-REF, will be presented at the European Society of Cardiology, or ESC, Congress 2014. The 8,442 patient study, PARADIGM-HF, was specifically designed to see if LCZ696 could increase survival over and above what can be achieved with ACE-inhibitor enalapril in addition to current best treatment in HF-REF patients. In March the Data Monitoring Committee overseeing the study confirmed those given LCZ696 were significantly less likely to die from CV causes, leading to the trial being closed early. LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF. PARADIGM-HF is the largest heart failure study ever conducted and was stopped early in March due to compelling efficacy. LCZ696 was recently granted FDA Fast Track status and rolling submission expected to be complete by end of year.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use